Madhuvilakku Rajesh

Dr. Madhuvilakku Rajesh

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Bioresource Technology
Verified
Journal Article
Closed access
MRMadhuvilakku Rajesh
Madhuvilakku Rajesh
SPShakkthivel Piraman
Shakkthivel Piraman

18 March 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
SASharmin Akter
Sharmin Akter
MRMadhuvilakku Rajesh
Madhuvilakku Rajesh
AKAnik Kumar Kar
Anik Kumar Kar
INIrin Sultana Nila
Irin Sultana Nila
Pengda LiuPengda Liu
Pengda Liu
Yonggeun HongYonggeun Hong
Yonggeun Hong
Reactive oxygen species (ROS) act as critical secondary messengers in various intracellular signaling pathways that regulate cellular proliferation, differentiation, and survival under normal physiological conditions. However, dysregulation of redox signaling—driven by genetic mutations, epigenetic alterations, and posttranscriptional or posttranslational modifications—plays a central role in malignant transformation and cancer progression. Cancer cells typically exhibit elevated basal ROS levels due to increased metabolic activity, mitochondrial dysfunction, and oncogene activation. This moderate oxidative stress promotes tumorigenesis by inducing DNA damage, genomic instability, and aberrant activation of proliferative and survival pathways, while also contributing to resistance to conventional therapies. Paradoxically, excessive ROS accumulation can overwhelm antioxidant defenses, triggering oxidative stress-induced programmed cell death (PCD) mechanisms, including apoptosis, autophagy, and ferroptosis. Owing to its dual role—facilitating both tumor progression and suppression—ROS have emerged as compelling yet complex targets in cancer therapy. Therapeutic strategies aimed at modulating ROS homeostasis, such as enhancing ROS production, inhibiting antioxidant systems, or targeting downstream redox-regulated signaling nodes, hold promise for selectively eliminating cancer cells. Furthermore, integrating redox profiling or “redox signatures” into personalized medicine approaches may optimize therapeutic efficacy while minimizing off-target toxicity. In this review, we critically examine the Janus-faced role of ROS in carcinogenesis, dissect the molecular pathways regulated by ROS in tumor biology, and explore current advancements, limitations, and future directions in redox-based anticancer therapeutic approaches.

1 January 2020 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MRMadhuvilakku Rajesh
Madhuvilakku Rajesh
SASrinivasan Alagar
Srinivasan Alagar
RMRamalakshmi Mariappan
Ramalakshmi Mariappan
SPShakkthivel Piraman
Shakkthivel Piraman

1 December 2018 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MRMadhuvilakku Rajesh
Madhuvilakku Rajesh
RMRamalakshmi Mariappan
Ramalakshmi Mariappan
SASrinivasan Alagar
Srinivasan Alagar
SPShakkthivel Piraman
Shakkthivel Piraman


2 December 2013 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Closed access
MRMadhuvilakku Rajesh
Madhuvilakku Rajesh
RMRamalakshmi Mariappan
Ramalakshmi Mariappan
SJSuganya Jeyapal
Suganya Jeyapal
SSSasikala Sundar
Sasikala Sundar
SPShakkthivel Piraman
Shakkthivel Piraman